Remission in schizophrenia: One-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder

Human Psychopharmacology

Volumn 24, Issue 7, 2009, Pages 574-583

  Rossi, Alessandro ^a   Bagalà, Anna ^b   Del Curatolo, Vincenzo ^c   Scapati, Francesco ^d   Bernareggi, Micaela Maria ^e   Giustra, Maria Grazia ^e  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b Mental Health Department   (Italy)

^c Mental Health Department   (Italy)

^d Mental Health Department   (Italy)

^e Janssen Cilag SpA Italia   (Italy)

Author keywords

Antipsychotics; DAI30; Long acting; PANSS; Remission; Schizophrenia

Indexed keywords

LONG ACTING DRUG; NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; AMENORRHEA; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GALACTORRHEA; HUMAN; IMPOTENCE; INSOMNIA; ITALY; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; MULTICENTER STUDY; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REMISSION; RESPIRATORY TRACT DISEASE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; ITALY; LOGISTIC MODELS; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TIME FACTORS; TREATMENT OUTCOME;

EID: 72849123567     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1067     Document Type: Article

References (33)

1. Andreasen NC, Carpenter WT, Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. 2005. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatr 162: 441-449. (Pubitemid 40343909)
2. APA. 1994. Diagnostic and Statistical Manual of Mental Disorders, IV. American Psychiatric Association: Washington, USA.
3. Ballenger JC. 2001. Overview of different pharmacotherapies for attaining remission in generalized anxiety disorder. J Clin Psychiatr 62 (Suppl 19): 11-19. (Pubitemid 32911035)
4. Chue P, Eerdekens M, Augustyns I, et al. 2005. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. European Neuropsych 15: 111-117. (Pubitemid 39574406)
5. Daneluzzo E, Arduini L, Rinaldi O, et al. 2002. PANSS factors and scores in schizophrenic and bipolar disorders during an index acute episode: a further analysis of the cognitive component. Schizophr Res 56: 129-136. (Pubitemid 34655475)
6. Davidson L, Schmutte T, Dinzeo T, Andres-Hyman R. 2008. Remission and recovery in schizophrenia: practitioner and patient perspectives. Schizophr Bull 34: 5-8. (Pubitemid 350262290)
7. Davis JM, Marder SR, Tamminga CA. 2006. Switch or stay? Am J Psychiatr 163: 2032-2033.
8. De Hert M, van Winkel R,Wampers M, Kane J, van Os J, Peuskens J. 2007. Remission criteria for schizophrenia: evaluation in a large naturalistic cohort. Schizophr Res 92: 68-73.
9. Docherty JP, Bossie CA, Lachaux B, et al. 2007. Patient-based and clinician-based support for the remission criteria in schizophrenia. Int Clin Psychopharmacol 22: 51-55. (Pubitemid 44950768)
10. Ehmann TS, Khanbhai I, Macewan GW, et al. 2004. Neuropsychological correlates of the PANSS Cognitive Factor. Psychopathology 37: 253-258. (Pubitemid 39370550)
11. Emsley R, Medori R, Koen L, Oosthuizen PP, Niehaus DJ, Rabinowitz J. 2008a. Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. J Clin Psychopharmacol 28: 210-213.
12. Emsley R, Oosthuizen PP, Koen L, Niehaus DJH, Medor R, Rabinowitz J. 2008b. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. Int Clin Psichoparmacol 23(6): 325-331.
13. Endicott J, Spitzer RL, Fleiss JL, Cohen J. 1976. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatr 33: 766-771.
14. Fleischhacker WW, Eerdekens M, Karcher K, et al. (2003). Treatment of schizophrenia with long acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 64: 1250-1257.
15. Guy W. 1976. Clinical Global Impressions. In: ECDEU Assessment Manual for Psychopharmacology. Revised 1976. DHEW publication No. (ADM) 76-338, 1976.
16. Helldin L, Kane JM, Karilampi U, Norlander T, Archer T. 2007. Remission in prognosis of functional outcome: a new dimension in the treatment of patients with psychotic disorders. Schizophr Res 93: 160-168. (Pubitemid 46817925)
17. Honer WG, Thornton AE, Sherwood M, et al. 2007. Conceptual and methodological issues in the design of clinical trials of antipsychotics for the treatment of schizophrenia. CNS Drugs 21: 699-714. (Pubitemid 47294717)
18. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. 2003. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatr 160: 1125-1132. (Pubitemid 41070972)
19. Kay SR. 1991. Positive and Negative Syndromes in Schizophrenia:. Assessment and Research, New York: Brunner/Mazel.
20. Keks N, Ingham M, Khan A, Karcher K. 2007. Long-acting injectable risperidone vs. olanzapine tablets for schizophrenia or schizoaffective disorder: British. J Psychiatr 191: 131-139.
21. Kissling W, Heres S, Lloyd K, et al. 2005. Direct transition to long-acting risperidone - analysis of long-term efficacy. J Psychopharmacol 19: 15-21.
22. Kupfer DJ. 1991. Long-term treatment of depression. J Clin Psychiatr 52 (Suppl:52) 28-34.
23. Lasser RA, Bossie CA, Gharabawi GM, Kane JM. 2005. Remission in schizophrenia: results from a 1-year study of long-acting risperidone injection. Schizophr Res 77: 215-227.
24. Lehman AF, Lieberman JA, Dixon LB, et al. 2004. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatr 161: 1-56.
25. Leucht S, Beitinger R, Kissling W. 2007. On the concept of remission in schizophrenia. Psychopharmacology (Berl) 194: 453-461.
26. Lieberman JA, Stroup TS, McEvoy JP, et al. 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223.
27. Llorca PM, Sacchetti E, Lloyd K, Kissling W, Medori R. 2008. Long-term remission in schizophrenia and related psychoses with long-acting risperidone: Results obtained in an open-label study with an observation period of 18 months. Int J Clin Pharmacol Ther 46: 14-22.
28. Moller HJ, Llorca PM, Sacchetti E, Martin SD, Medori R, Parellada E. 2005. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol 20: 121-130.
29. Pancheri P, Brugnoli R, Carilli L, Delle Chiaie R, Marconi PL, Petrucci RM. 1995. Valutazione dimensionale della sintomatologia schizofrenica. Giorn Ital Psicopat 1-3: 60-76.
30. Remington G, Kapur S. 2005. Remission: what's in a name. Am J Psychiatr 162: 2393-2394.
31. Rossi A, Arduini L, De Cataldo S, Stratta P. 2001. Subjective response to neuroleptic medication: a validation study of the Italian version of the drug attitude inventory (DAI). Epidemiol Psichiatr Soc 10: 107-114.
32. Sethuraman G, Taylor CC, Enerson M, Dunayevich E. 2005. A retrospective comparison of cumulative time spent in remission during treatment with olanzapine or risperidone among patients with schizophrenia. Schizophr Res 79: 337-340.
33. Van Os J, Drukker M, Campo J, Meijer J, Bak M, Delespaul P. 2006. Validation of remission criteria for schizophrenia. Am J Psychiatr 163: 2000-2002.